menu search

GSK / GSK scores phase III success with meningococcal disease vaccine

GSK scores phase III success with meningococcal disease vaccine
GSK PLC (LSE:GSK, NYSE:GSK) has announced positive results from its phase III trial of its MenABCWY combination vaccine candidate in meningococcal, a major cause of meningitis and septicaemia. The drug, a five-in-one amalgam of treatments, was administered in two doses given six months apart. Read More
Posted: Mar 14 2023, 03:43
Author Name: Proactive Investors
Views: 103029

GSK News  

GSK falls victim of ‘hard to please' pharma market

By Proactive Investors
November 2, 2023

GSK falls victim of ‘hard to please' pharma market

GSK PLC (LSE:GSK, NYSE:GSK)'s seemingly positive earnings release on Wednesday has been labelled as just that by Stifel analysts, who were left mullin more_horizontal

GSK Beats on Q3 Earnings and Sales, Raises 2023 Guidance

By Zacks Investment Research
November 1, 2023

GSK Beats on Q3 Earnings and Sales, Raises 2023 Guidance

GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales on more_horizontal

GSK receives a mixed City reaction despite raised outlook

By Proactive Investors
November 1, 2023

GSK receives a mixed City reaction despite raised outlook

GSK PLC (LSE:GSK, NYSE:GSK) has received mixed reactions from City analysts despite an objectively strong third-quarter performance and raised financi more_horizontal

GSK (GSK) Q3 Earnings and Revenues Surpass Estimates

By Zacks Investment Research
November 1, 2023

GSK (GSK) Q3 Earnings and Revenues Surpass Estimates

GSK (GSK) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $ more_horizontal

GSK Boosts Profit Forecasts After ‘Outstanding' RSV Vaccine Launch

By Forbes
November 1, 2023

GSK Boosts Profit Forecasts After ‘Outstanding' RSV Vaccine Launch

High demand for the vaccine pulled in around $850 million during the third quarter—reportedly double what analysts were expecting—and GSK said ann more_horizontal

GSK raises outlook amid strong demand for new RSV vaccine

By Proactive Investors
November 1, 2023

GSK raises outlook amid strong demand for new RSV vaccine

GSK PLC (LSE:GSK, NYSE:GSK) said a strong third quarter performance has driven a further upgrade to full-year guidance boosted by demand for its respi more_horizontal

GSK raises annual forecasts again on strong Arexvy launch

By Reuters
November 1, 2023

GSK raises annual forecasts again on strong Arexvy launch

GSK raised its full-year profit and sales forecasts on Wednesday for the second time this year, betting on the strong launch of its respiratory syncyt more_horizontal

GSK Reports Earnings Wednesday. What to Watch.

By Barrons
October 31, 2023

GSK Reports Earnings Wednesday. What to Watch.

The company will for the first time report sales of Arexvy, its new RSV vaccine that launched this fall. more_horizontal


Search within

Pages Search Results: